Annovis Bio Inc (ANVS)
NYSEHealth CareBiotechnologySnapshot 2026-11-05
$0.67-44.72%
Close 2026-11-05 · 1-day change
NYSEHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · ANVS
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(-12.5) + peer(0.2*4.9) + term(0.0) → -3.4% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
in 5 days
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Provisional scorecard: fewer than 4 guided quarters in the corpus.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. Annovis Bio, Inc. (the “Company”) is providing the following information about its preliminary cash and cash equivalents as of September 30, 2026. Based on preliminary estimates and currently available information, the Company estimates that its cash and cash equivalents were approximately $2.8 million as of September 30, 2026. The Company’s interim financial statements as of and for the three and nine months ended September 30, 2026 are not yet…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On August 14, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On May 15, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On March 16, 2026, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On November 12, 2025, Annovis Bio, Inc. (the “Registrant”) issued a press release reporting earnings for the quarter and nine months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99 hereto and incorporated herein by reference.
Results of Operations and Financial Condition. On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition. On May 13, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition. On March 21, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the fourth quarter and the fiscal year ended December 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition On November 11, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition On August 15, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition On May 13, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition On April 2, 2024, Annovis Bio, Inc. issued a press release announcing its financial results for the fourth quarter and the fiscal year ended December 31, 2023 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
Results of Operations and Financial Condition. The Company estimates that its cash and cash equivalents were approximately $6.355 million as of September 30, 2023. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company’s financial statements as of and for the quarter ended September 30, 2023. The information in this
Results of Operations and Financial Condition. On April 3, 2023, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise su…
Results of Operations and Financial Condition. On August 8, 2022, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2022 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the…
Results of Operations and Financial Condition. On May 4, 2022, Annovis Bio, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2022 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the l…